Related Experiment Video

Updated: Jul 9, 2026

Microbiological Rapid On-Site Evaluation for Pulmonary Infectious Diseases
03:22

Microbiological Rapid On-Site Evaluation for Pulmonary Infectious Diseases

Published on: March 1, 2024

Optimizing therapy for MRSA pneumonia

Lee P Skrupky1, Scott T Micek, Marin H Kollef

  • 1Department of Pharmacy, Barnes-Jewish Hospital, 216 S. Kingshighway Boulevard, St. Louis, MO 63110, USA.

Seminars in Respiratory and Critical Care Medicine
|December 21, 2007
PubMed

Insights

Methicillin-resistant Staphylococcus aureus (MRSA) causes severe pneumonia. Vancomycin treatment failures are rising, prompting investigation into alternative therapies like linezolid for better MRSA pneumonia outcomes.

Area of Science:

  • Infectious Diseases
  • Pulmonology
  • Pharmacology

Background:

  • Staphylococcus aureus is a leading cause of diverse pneumonia types.
  • Increasing methicillin resistance complicates treatment and prevention of MRSA pneumonia.
  • Community-associated MRSA (CA-MRSA) presents unique clinical challenges.

Purpose of the Study:

  • To review the epidemiology of MRSA pneumonia.
  • To discuss current and emerging pharmacotherapies for MRSA pneumonia.
  • To highlight challenges in treating MRSA pneumonia.

Main Methods:

  • Literature review of MRSA pneumonia epidemiology.
  • Analysis of pharmacotherapeutic options for MRSA pneumonia.
  • Examination of factors influencing vancomycin efficacy and failure.

Main Results:

  • Vancomycin, a first-line agent, faces increasing resistance and therapeutic failures.
  • Factors influencing vancomycin outcomes include isolate genetics, lung penetration, and PK/PD variables.
  • Retrospective data suggest linezolid may outperform vancomycin, pending prospective trials.

Conclusions:

  • MRSA pneumonia treatment is challenging due to rising resistance and vancomycin limitations.
  • Further research and clinical trials are needed to validate alternative therapies.
  • Optimizing pharmacotherapy is crucial for improving MRSA pneumonia patient outcomes.

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...